Trogocytosis-orchestrated CLDN18.2-"dressed" CD8 T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade.
[BACKGROUND] As it is a tumour-associated antigen in epithelial cells, research on claudin18.2 (CLDN18.2) has focused on its role as a therapeutic target in pancreatic cancers and its part in maintain
APA
Zhou T, Yan J, et al. (2026). Trogocytosis-orchestrated CLDN18.2-"dressed" CD8 T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade.. Gut. https://doi.org/10.1136/gutjnl-2025-335790
MLA
Zhou T, et al.. "Trogocytosis-orchestrated CLDN18.2-"dressed" CD8 T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade.." Gut, 2026.
PMID
41667243
Abstract
[BACKGROUND] As it is a tumour-associated antigen in epithelial cells, research on claudin18.2 (CLDN18.2) has focused on its role as a therapeutic target in pancreatic cancers and its part in maintaining tight junctions.
[OBJECTIVE] We elucidate the role of trogocytosis-related CLDN18.2 in CD8 T cells and pancreatic ductal adenocarcinoma (PDAC) progression.
[DESIGN] We constructed humanised hCD34, Trp53KrasPdx1-cre (KPC), Cldn18.2 knockout (KO), and patient-derived xenograft/organoid mouse models. Flow cytometry, immunofluorescence, single-cell RNA-sequencing and immunoprecipitation-mass spectrometry (IP-MS) were performed.
[RESULTS] CLDN18.2CD8 T cells indicated poor pancreatic cancer prognosis and immunotherapeutic resistance. CD8 T cells acquired CLDN18.2 from tumour cells via trogocytosis, inhibiting their activation and cytotoxicity. "Dressed" CLDN18.2 suppressed glucose uptake, glycolysis and cytotoxicity of tumour-infiltrating CD8 T cells. Mechanically, trogocytosis-related CLDN18.2 induced GSK3β/CK1α-mediated β-catenin phosphorylation, promoting β-catenin ubiquitination and proteasome degradation in CD8 T cells. CLDN18.2 interacted with β-catenin's N-terminal domain via its C-terminal domain, further strengthening the interaction between β-catenin and CK1α. Moreover, CLDN18.2CD8 T cells preferentially 'homed' to the bone marrow through the CXCL12/CXCR4 axis, skewed haematopoietic stem cell myeloid differentiation and induced systemic immune senescence via IL1α. Notably, preclinical mouse studies showed PC18.1 peptide sensitised immunotherapy and suppressed PDAC progression by disrupting the CLDN18.2/β-catenin interaction in CD8 T cells.
[CONCLUSIONS] Trogocytosis-related CLDN18.2 inhibited the glucose uptake, glycolysis and cytotoxicity of tumour-infiltrating CD8 T cells by promoting the ubiquitin-proteasomal degradation of β-catenin in PDAC. Therefore, targeting trogocytosis-related CLDN18.2CD8 T cells may be a promising therapeutic strategy to inhibit PDAC progression.
[OBJECTIVE] We elucidate the role of trogocytosis-related CLDN18.2 in CD8 T cells and pancreatic ductal adenocarcinoma (PDAC) progression.
[DESIGN] We constructed humanised hCD34, Trp53KrasPdx1-cre (KPC), Cldn18.2 knockout (KO), and patient-derived xenograft/organoid mouse models. Flow cytometry, immunofluorescence, single-cell RNA-sequencing and immunoprecipitation-mass spectrometry (IP-MS) were performed.
[RESULTS] CLDN18.2CD8 T cells indicated poor pancreatic cancer prognosis and immunotherapeutic resistance. CD8 T cells acquired CLDN18.2 from tumour cells via trogocytosis, inhibiting their activation and cytotoxicity. "Dressed" CLDN18.2 suppressed glucose uptake, glycolysis and cytotoxicity of tumour-infiltrating CD8 T cells. Mechanically, trogocytosis-related CLDN18.2 induced GSK3β/CK1α-mediated β-catenin phosphorylation, promoting β-catenin ubiquitination and proteasome degradation in CD8 T cells. CLDN18.2 interacted with β-catenin's N-terminal domain via its C-terminal domain, further strengthening the interaction between β-catenin and CK1α. Moreover, CLDN18.2CD8 T cells preferentially 'homed' to the bone marrow through the CXCL12/CXCR4 axis, skewed haematopoietic stem cell myeloid differentiation and induced systemic immune senescence via IL1α. Notably, preclinical mouse studies showed PC18.1 peptide sensitised immunotherapy and suppressed PDAC progression by disrupting the CLDN18.2/β-catenin interaction in CD8 T cells.
[CONCLUSIONS] Trogocytosis-related CLDN18.2 inhibited the glucose uptake, glycolysis and cytotoxicity of tumour-infiltrating CD8 T cells by promoting the ubiquitin-proteasomal degradation of β-catenin in PDAC. Therefore, targeting trogocytosis-related CLDN18.2CD8 T cells may be a promising therapeutic strategy to inhibit PDAC progression.
같은 제1저자의 인용 많은 논문 (5)
- Safety and Efficacy of Lucitanib Plus Toripalimab in Advanced Solid Tumors Refractory to Standard Therapies: An Open-Label, Multicenter, Phase II Study.
- Quantitative reverse transcription PCR coupled with high-resolution melting for simultaneous detection and quantification of four isoforms of BCR::ABL1.
- Senescent cancer-associated fibroblasts drive early-stage lymph node metastasis in pancreatic cancer through lactate-mediated metabolic-epigenetic rewiring.
- Knockdown of EFEMP1 Promotes Ferroptosis by Inactivating PI3K/AKT to overcome the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
- Analysis of the pathological composition ratio of orbital space-occupying lesions in 7 515 cases: single-center retrospective study.